Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Osteoarthritis Pipeline Market H1 2016 Global Review Report
  • India - English


News provided by

ReportsnReports

Apr 28, 2016, 02:00 ET

Share this article

Share toX

Share this article

Share toX

PUNE, India, April 28, 2016 /PRNewswire/ --

New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Company Profiles discussed in this H1 2016 Osteoarthritis Pipeline report include A. Menarini Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., Addex Therapeutics Ltd, Akari Therapeutics, Plc, Amura Holdings Limited, Arcarios BV, Asahi Kasei Pharma Corp., Asklepios BioPharmaceutical, Inc., Astellas Pharma Inc., Asterias Biotherapeutics, Inc., Axsome Therapeutics, Inc., Biopharm GmbH, Can-Fite BioPharma Ltd., Cara Therapeutics, Inc., Cardax Pharmaceuticals, Inc., Cellceutix Corporation, Cellular Biomedicine Group, Inc., Chong Kun Dang Pharmaceutical Corp., Dong-A ST Co., Ltd., Eli Lilly and Company, Evgen Pharma PLC, Galapagos NV, Genequine Biotherapeutics GmbH, GlaxoSmithKline Plc, IntelliCell BioSciences Inc., Jeil Pharmaceutical Co., Ltd., Jenrin Discovery, Inc., K-Stemcell Co., Ltd., Levolta Pharmaceuticals, Inc., Medivir AB, Merck KGaA, Mesoblast Limited, Mor Research Application Ltd, NicOx S.A., Nordic Bioscience A/S, Novartis AG, Ocata Therapeutics, Inc., Omeros Corporation, Ono Pharmaceutical Co., Ltd., OrthoCyte Corporation, Osteologix Holdings Plc, Pfizer Inc., Pharmalink AB, PLx Pharma Inc., ProteoThera, Inc., Regeneus Ltd, ReqMed Company, Ltd., Sanofi, Seikagaku Corporation, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., STELIS Biopharma Pvt. Ltd., Stempeutics Research Private Limited, Symic Biomedical, Inc., Takeda Pharmaceutical Company Limited, TissueGene, Inc., Upsher-Smith Laboratories, Inc., Yooyoung Pharmaceutical Co., Ltd., Yuhan Corporation, Yungjin Pharm. Co., Ltd., Zimmer Biomet Holdings, Inc. and Zynerba Pharmaceuticals, Inc.

Complete report on H1 2016 pipeline review of Osteoarthritis with 102 market data tables and 17 figures, spread across 108 pages is available at http://www.reportsnreports.com/reports/531489-osteoarthritis-pipeline-review-h1-2016.html .

Drugs Profiles discussed in this report include (apocynin + paeonol), (clodronate disodium + hyaluronic acid), ABT-981, AlloJoin, AM-3701, AM-3876, Anatabine, Antibody for Osteoarthritis, Antibody to Inhibit TGF-Beta 1 for Osteoarthritis, ARC, AS-001, ASP-7962, BNP-OA, BRM-421, CDX-085, celecoxib, CHND-1, CKD-941, clodronate disodium, CR-8357, CR-845, CRB-0017, CS-30MS02, DA-5202, DIS-BIO-EPS, DNX-314, Drug for Bone Diseases and Osteoarthritis, Drug for Osteoarthritis, Drugs to Inhibit Renin Angiotensin for Osteoarthritis, Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture, Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders, duloxetine hydrochloride DR, fasitibant chloride, GLPG-1972, GQ-203, GQ-303, GSK-2394002, GZ-389988, JD-4000 Series, Kartogenin, KBP-056, ketoprofen, KM-278, LEVI-04, LH-023, LNA-043, MIV-711, Monoclonal Antibodies for Inflammation and Osteoarthritis, Monoclonal Antibody for Osteoarthritis, MOR-106, MSBCAR-001, naproxcinod, NBS-101, NStride APS, OAX-1, ONO-4474, OTXCP-03, OTXCP-07, pentosan polysulfate sodium, Peptide for Osteoarthritis, piclidenoson, PL-1100, PRO-1, Progenza, Protein for Osteoarthritis, Protein for Osteoarthritis and Asthma, Protein for Rheumatoid Arthritis and Osteoarthritis, Protein to Activate BMP-7 for Obesity, Osteoarthritis, Kidney Fibrosis and Alport Syndrome, PRX-167700, Recombinant Peptides for Osteoarthritis, Recombinant Protein to Activate IL-4 and IL-10 Receptors for Osteoarthritis and CNS, Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis, Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis, ReJoin, Salmon Calcitonin, SAR-396049, SB-061, SBL-005, SI-613, SM-04690, Small Molecule for Degenerative Arthritis, Small Molecule for Osteoarthritis, Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders, Small Molecule to Inhibit MMP13 for Osteoarthritis, Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis, Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders, Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders, Small Molecules for Osteoarthritis, Small Molecules to Antagonize TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders, Small Molecules to Inhibit ADAMTS-5 for Osteoarthritis, Small Molecules to Inhibit Complement System Protein for Osteoarthritis, Small Molecules to Inhibit Kinase for Osteoarthritis and Osteoporosis, Small Molecules to Inhibit MMP-13 for Osteoarthritis, sprifermin, Stem Cell Therapy for Autoimmune Diseases, Stem Cell therapy for CNS, CVS, Dermatological, Immnuological and Metabolic Disorders, Stem Cell Therapy for Degenerative Arthritis, Stem Cell Therapy for Knee Osteoarthritis, Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Osteoarthritis, Autism, Bronchopulmonary Dysplasia, Heart Failure and Cerebral Palsy, Stem Cell Therapy for Osteoarthritis, Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure, Post Cardiopulmonary Resuscitation and Neurodegenerative Diseases, Stempeucel, Stromal Cell Therapy for Arthritis, Sulforadex, tonogenchoncel-L, TPX-100, TRBN-0224, UGP-302, VOLT-01, X-0002, XT-101, XT-150, YH-14619, YRA-1909, YY-1201, zoledronic acid and ZYN-002.

Order a copy of H1 2016 Osteoarthritis pipeline market research report @ http://www.reportsnreports.com/Purchase.aspx?name=531489 .

This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Explore more reports on Pharmaceuticals.

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:
Facebook: https://www.facebook.com/ReportsnReports/
LinkedIn: https://www.linkedin.com/company/reportsnreports
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
[email protected]

SOURCE ReportsnReports

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.